

Investment in Theramir Ltd

Current report No 5/2023

Date: 2023-03-28

Title: Investment in Theramir Ltd

Legal basis: Art. 17 ust.1 MAR – inside information

Message:

The Board of Directors of ASBISc Enterprises Plc (“ASBIS”) hereby informs that ASBIS signed an agreement according to which acquired 4.5% shares of the company Theramir Ltd with its registered office in Limassol (Cyprus).

The price for the purchased shares was EUR 800,000.

The acquisition was financed from the own Company's funds. Theramir Ltd is a Cypriot biotech company, founded in 2016, that deals with developing stem cell and RNA-based technologies for the diagnosis and treatment of cancer disease. Theramir's proprietary cancer therapeutics utilize microRNAs (miRNAs), a novel class of small non-coding RNAs that can regulate many genes and pathways involved in cancer growth and metastasis.

The investment in Theramir Ltd is a continuity of the ASBIS Group's strategy is to diversify its activities by investing in companies from the biomedical sector that are at an early stage of development and which operate in a very promising market.

In previous years ASBIS invested in biotechnology, companies including EMBIO Diagnostics Ltd, RSL Revolutionary Labs Ltd. and Promed Bioscience Ltd.

Regulated

Publication Date: 28/03/2023